Patients with atrial fibrillation – an irregular and often abnormally fast heartbeat – have nearly double the risk of suffering a stroke in the first 30 days after starting to take the anti-clotting drug warfarin compared to non-users, according to a study of over 70,000 patients.
The study, published online today (Thursday) in the European Heart Journal, found that the risk was particularly high in the first week after patients started to take the drug. In contrast, once the first 30 days had elapsed, the risk of a stroke was halved in patients taking warfarin compared to non-users.
Atrial fibrillation increases the risk of patients suffering a stroke, and warfarin is frequently prescribed for these patients to reduce the likelihood of this happening. However, randomised controlled trials of other anti-clotting drugs have suggested that there might be an increased risk of a stroke at the point when patients move from the trial drugs to warfarin. In addition, it has already been established that there is a possibility that warfarin leads temporarily to a hypercoagulable state – one in which the blood becomes more sticky and more likely to develop dangerous blood clots in the veins or arteries. This is thought to be due to the different effects of warfarin on the production of certain blood clotting factors that are dependent on Vitamin K.
Dr Laurent Azoulay, Assistant Professor in the Department of Oncology at McGill University (Montreal, Canada) and Project Leader at the Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital in Montreal, led the research. "There is no question that warfarin is highly effective in preventing strokes in patients with atrial fibrillation. Thus, our finding that the initiation of warfarin may be associated with an increased risk of stroke should not deter physicians and patients from using this drug, since this likely affects a small number of patients. Future studies should confirm our results, and identify the small subset of patients who may be at risk. However, the results of our study suggest that physicians should be vigilant when initiating warfarin, particularly in the first week of use," he said.
"An interesting finding was that patients with a history of stroke prior to their atrial fibrillation diagnosis were at higher increased risk of developing a stroke during the initiation of warfarin. This is consistent with the hypothesis that the risk may be highest in patients with hypercoagulable states, which provides insight on the possible biological mechanisms that may be at play in this association.
"To our knowledge, this is the first population-based study to investigate whether the initiation of warfarin is associated with an increased risk of ischaemic stroke – a stroke caused by a blockage in an artery leading to the brain."
The researchers analysed data from 70,766 patients aged 18 or over, who were diagnosed with atrial fibrillation between 1 January 1993 and 31 December 2008. The study was carried out using the UK Clinical Practice Research Datalink, the world's largest primary care database. The researchers followed the patients for up to 16 years until an ischaemic stroke, death, end of registration with their primary care practice or end of the study period, whichever came first.
During that time, a total of 5519 patients experienced a stroke (two percent per year). During the first 30 days after starting warfarin, there was a 71% (nearly double) increased risk of ischaemic stroke when compared with patients taking no anti-coagulant drugs. The highest risk was in the first week of use, peaking on the third day after starting warfarin when there was a 133% (2.3-fold) increased risk of stroke. After 30 days, the risk of stroke among the warfarin patients halved. If the patients had a history of previous ischaemic stroke, they had a 245% (2.5-fold) increased risk during the first 30 days.
The researchers believe that the reason for the difference in the effects of warfarin may be that while the drug blocks the activation of clotting factors II, VII, IX and X, it also deactivates two other proteins, C and S, which are anticoagulants. Rapid depletion of protein C, in particular, might lead to a temporary hypercoagulable state.
The senior author of the study, Professor Samy Suissa, James McGill Professor of Epidemiology, Biostatistics and Medicine at McGill University (Montreal, Canada), said: "While these findings need to be confirmed in other settings, it would be imperative to also investigate whether the newer popular anticoagulants also carry this early risk." In the meantime, he suggests that "a bridging strategy using heparin – an injectable anticoagulant – at the initiation of warfarin treatment could be considered as a way to reduce the increased risk observed in the first 30 days of use."
The researchers hope to repeat the study using databases from other countries and settings.
Explore further: Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation
More information: "Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes", by Laurent Azoulay, Sophie Dell'Anielllo, Teresa A. Simon, Christel Renoux, and Samy Suissa. European Heart Journal. DOI: 10.1093/eurheartj/eht499
Medical Xpress on facebook
Related Stories
Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation
Nov 19, 2013
According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious long-term disability and death in the US. ...
Apixaban superior to warfarin across range of patient risk scores
Oct 01, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...
Major risks of dual and triple antithrombotic therapy in patients with newly diagnosed atrial fibrillation
Mar 05, 2013
According to Dr. Samy Suissa, Director of Clinical Epidemiology, Jewish General Hospital, and Professor of Epidemiology, McGill University in Montreal, Canada, "treating physicians need to consider the clinical effectiveness ...
Stroke risk high when anti-clotting drugs stopped
Apr 25, 2012
Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...
Clot-busting medicine safe for use in warfarin-treated patients following stroke
Jun 26, 2012
The clot-busting medicine, tPA (tissue plasminogen activator), is safe to use in acute stroke patients already on the home blood thinner warfarin, according to researchers from Duke Clinical Research Institute (DCRI). This ...
Recommended for you
Heart disease and stroke continue to threaten US health
2 hours ago
Heart disease and stroke remain two of the top killers of Americans and pose a significant threat to millions of others, according to the American Heart Association's Heart Disease and Stroke Statistical Update 2014, published ...
Heart disease linked with dementia in older postmenopausal women
2 hours ago
Heart disease may put older postmenopausal women at higher risk for decreased brain function such as dementia, according to new research in Journal of the American Heart Association.
Higher blood pressure threshold OK in older adults (Update)
9 hours ago
Many older adults with high blood pressure can be treated less aggressively, which could mean taking fewer pills to get it under control, according to new treatment guidelines from a U.S. expert panel. But not all experts ...
Going against the flow: Halting atherosclerosis by targeting micro RNA
13 hours ago
Researchers at Emory and Georgia Tech have developed a potential treatment for atherosclerosis that targets a master controller of the process.
An apple a day keeps the doctor away: 150 year old proverb stands the test of time, say researchers
Dec 17, 2013
Prescribing an apple a day to all adults aged 50 and over would prevent or delay around 8,500 vascular deaths such as heart attacks and strokes every year in the UK – similar to giving statins to everyone over 50 years ...
Atrial fibrillation is a growing global health concern
Dec 17, 2013
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, ...
User comments
© Medical Xpress 2011-2013, Science X network
Patients with atrial fibrillation – an irregular and often abnormally fast heartbeat – have nearly double the risk of suffering a stroke in the first 30 days after starting to take the anti-clotting drug warfarin compared to non-users, according to a study of over 70,000 patients.
The study, published online today (Thursday) in the European Heart Journal, found that the risk was particularly high in the first week after patients started to take the drug. In contrast, once the first 30 days had elapsed, the risk of a stroke was halved in patients taking warfarin compared to non-users.
Atrial fibrillation increases the risk of patients suffering a stroke, and warfarin is frequently prescribed for these patients to reduce the likelihood of this happening. However, randomised controlled trials of other anti-clotting drugs have suggested that there might be an increased risk of a stroke at the point when patients move from the trial drugs to warfarin. In addition, it has already been established that there is a possibility that warfarin leads temporarily to a hypercoagulable state – one in which the blood becomes more sticky and more likely to develop dangerous blood clots in the veins or arteries. This is thought to be due to the different effects of warfarin on the production of certain blood clotting factors that are dependent on Vitamin K.
Dr Laurent Azoulay, Assistant Professor in the Department of Oncology at McGill University (Montreal, Canada) and Project Leader at the Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital in Montreal, led the research. "There is no question that warfarin is highly effective in preventing strokes in patients with atrial fibrillation. Thus, our finding that the initiation of warfarin may be associated with an increased risk of stroke should not deter physicians and patients from using this drug, since this likely affects a small number of patients. Future studies should confirm our results, and identify the small subset of patients who may be at risk. However, the results of our study suggest that physicians should be vigilant when initiating warfarin, particularly in the first week of use," he said.
"An interesting finding was that patients with a history of stroke prior to their atrial fibrillation diagnosis were at higher increased risk of developing a stroke during the initiation of warfarin. This is consistent with the hypothesis that the risk may be highest in patients with hypercoagulable states, which provides insight on the possible biological mechanisms that may be at play in this association.
"To our knowledge, this is the first population-based study to investigate whether the initiation of warfarin is associated with an increased risk of ischaemic stroke – a stroke caused by a blockage in an artery leading to the brain."
The researchers analysed data from 70,766 patients aged 18 or over, who were diagnosed with atrial fibrillation between 1 January 1993 and 31 December 2008. The study was carried out using the UK Clinical Practice Research Datalink, the world's largest primary care database. The researchers followed the patients for up to 16 years until an ischaemic stroke, death, end of registration with their primary care practice or end of the study period, whichever came first.
During that time, a total of 5519 patients experienced a stroke (two percent per year). During the first 30 days after starting warfarin, there was a 71% (nearly double) increased risk of ischaemic stroke when compared with patients taking no anti-coagulant drugs. The highest risk was in the first week of use, peaking on the third day after starting warfarin when there was a 133% (2.3-fold) increased risk of stroke. After 30 days, the risk of stroke among the warfarin patients halved. If the patients had a history of previous ischaemic stroke, they had a 245% (2.5-fold) increased risk during the first 30 days.
The researchers believe that the reason for the difference in the effects of warfarin may be that while the drug blocks the activation of clotting factors II, VII, IX and X, it also deactivates two other proteins, C and S, which are anticoagulants. Rapid depletion of protein C, in particular, might lead to a temporary hypercoagulable state.
The senior author of the study, Professor Samy Suissa, James McGill Professor of Epidemiology, Biostatistics and Medicine at McGill University (Montreal, Canada), said: "While these findings need to be confirmed in other settings, it would be imperative to also investigate whether the newer popular anticoagulants also carry this early risk." In the meantime, he suggests that "a bridging strategy using heparin – an injectable anticoagulant – at the initiation of warfarin treatment could be considered as a way to reduce the increased risk observed in the first 30 days of use."
The researchers hope to repeat the study using databases from other countries and settings.
Explore further: Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation
More information: "Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes", by Laurent Azoulay, Sophie Dell'Anielllo, Teresa A. Simon, Christel Renoux, and Samy Suissa. European Heart Journal. DOI: 10.1093/eurheartj/eht499
Medical Xpress on facebook
Related Stories
Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation
Nov 19, 2013
According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious long-term disability and death in the US. ...
Apixaban superior to warfarin across range of patient risk scores
Oct 01, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...
Major risks of dual and triple antithrombotic therapy in patients with newly diagnosed atrial fibrillation
Mar 05, 2013
According to Dr. Samy Suissa, Director of Clinical Epidemiology, Jewish General Hospital, and Professor of Epidemiology, McGill University in Montreal, Canada, "treating physicians need to consider the clinical effectiveness ...
Stroke risk high when anti-clotting drugs stopped
Apr 25, 2012
Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...
Clot-busting medicine safe for use in warfarin-treated patients following stroke
Jun 26, 2012
The clot-busting medicine, tPA (tissue plasminogen activator), is safe to use in acute stroke patients already on the home blood thinner warfarin, according to researchers from Duke Clinical Research Institute (DCRI). This ...
Recommended for you
Heart disease and stroke continue to threaten US health
2 hours ago
Heart disease and stroke remain two of the top killers of Americans and pose a significant threat to millions of others, according to the American Heart Association's Heart Disease and Stroke Statistical Update 2014, published ...
Heart disease linked with dementia in older postmenopausal women
2 hours ago
Heart disease may put older postmenopausal women at higher risk for decreased brain function such as dementia, according to new research in Journal of the American Heart Association.
Higher blood pressure threshold OK in older adults (Update)
9 hours ago
Many older adults with high blood pressure can be treated less aggressively, which could mean taking fewer pills to get it under control, according to new treatment guidelines from a U.S. expert panel. But not all experts ...
Going against the flow: Halting atherosclerosis by targeting micro RNA
13 hours ago
Researchers at Emory and Georgia Tech have developed a potential treatment for atherosclerosis that targets a master controller of the process.
An apple a day keeps the doctor away: 150 year old proverb stands the test of time, say researchers
Dec 17, 2013
Prescribing an apple a day to all adults aged 50 and over would prevent or delay around 8,500 vascular deaths such as heart attacks and strokes every year in the UK – similar to giving statins to everyone over 50 years ...
Atrial fibrillation is a growing global health concern
Dec 17, 2013
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment